- Home
- Primary Care
- Long-Term Safety Outcomes from Phase 2b Trial of Oral Ritlecitinib in Vitiligo

3w3 min read
Medical Article
Vitiligo is a chronic autoimmune disease involving progressive loss of melanocytes and can impose a significant psychological burden on affected patients (1). The interferon-gamma (IFN-ɣ) driven CD8+ T cell activation via the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway plays a central role in the pathogenesis of

Long-Term Safety Outcomes from Phase 2b Trial of Oral Ritlecitinib in Vitiligo
18 Reached
Similar Content

Woman presented with Fever of Unknown Origin
7717 Reached93 Comments19 Likes

How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes

Rubella Syndrome in Neonate
1396 Reached12 Comments9 Likes

Black Lesion in Old Female
1970 Reached5 Comments11 Likes

Chronic Hyperplastic Candidiasis Of The Oral Mucosa
857 Reached9 Comments11 Likes